FDA recommends approval for Second Sight's Argus II retinal prosthesis system in the US
On Friday September 28, a U.S. Food and Drug Administration (FDA) Ophthalmic Devices Advisory Panel unanimously voted 19-0 that the probable benefit of the Argus II Retinal Prosthesis System outweighs the risks to health, an important step toward the FDA market approval of this product manufactured by Second Sight Medical Products, Inc. In making this determination, the panel spent ten hours carefully reviewing and discussing data submitted from the international clinical trial of this innovative retinal implant that, for the first time ever, partially restores vision to patients who are blind due to Retinitis Pigmentosa (RP).
"We are very pleased with the panel recommendation today. The panel deliberations were well informed and thorough and their decision validated over two decades of work by Second Sight and our collaborators," said Robert Greenberg, MD, PhD, President and CEO of Second Sight. "We would also like to thank all of the people around the world with Retinitis Pigmentosa who volunteered to participate in our clinical trials, and the doctors who treated them. Without their pioneering efforts, today's result would not have been possible."
The panel, which was comprised of 19 voting members with expertise in ophthalmology, retinal disease, low vision, electrophysiology and other specialties heard testimony from Second Sight, the US Food and Drug Administration, and several doctors and participants involved in the most recent clinical trial that began in 2007. After hearing the testimony, asking questions, discussing concerns, and carefully deliberating, the panel voted unanimously that the probable benefit of the Argus II Retinal Prosthesis System outweighs the risks to health. This recommendation came after more than 20 years of work in the field, $200M of public and private investment, and 10 years after the first person received Second Sight's first Bionic Eye in the clinical trial of the first generation Argus I retinal implant which began in 2002. Many of the hundreds of people that have played instrumental roles in the development of Argus II were moved by the panel recommendation.
"While the European Approval last year was based on the safety and the long term performance of the Argus II Retinal Prosthesis System, the FDA panel required the demonstration of probable benefit as well. This recommendation will now give us the chance to improve the quality of life of thousands of blind patients who have absolutely no other treatment options", said Dr. Lyndon da Cruz, MD PhD Consultant Retinal Surgeon at Moorfields Eye Hospital in London, UK who presented the international trial data to the FDA panel in Washington. "The landmark nature of the moment was reflected by one of the largest FDA panels ever convened and there were numerous patients who had benefitted from the device giving moving testimonies of how the device had changed their lives".
"With seven patients treated in Moorfields Eye Hospital, the largest clinical site in the world, I am very proud to have participated in the world's biggest trial of any retinal implant, and that our research work in the NHS has been seminal in allowing blind patients around the world to get access to this unique and life changing treatment. With both European and recommended US market approval of Second Sight's Argus II bionic eye an historical first has been achieved. We can now begin to see great hope in the future development of this field and the promise of restoration of sight for those who need it most".
Professor Paulo Stanga, Vitreoretinal Surgeon at Manchester Royal Eye Hospital and Director of the Manchester Vision Regeneration (MVR) Lab, UK, added, "In Manchester, we enrolled three subjects in this trial, and obtained some tremendous results. In further research, we have been able to demonstrate that patients blinded by retinitis pigmentosa could consistently perceive different colors at the same time using Argus II. This data is very encouraging because it suggests the possibility that Argus II with its software capability could be upgraded to one day restore color vision for these blind patients."
"I think it's a terrific system, it's wonderful, it's changed my life. I just like to be part of something that does something for other patients with retinitis pigmentosa" said Keith from Manchester, user of the system since 2009, in a statement to the FDA panel.
"This is a truly exciting and historic moment for people with advanced inherited retinal degenerations such as retinitis pigmentosa," said Dr. Stephen Rose, chief research officer, Foundation Fighting Blindness, which helped get the project started with early support.
RP, an inherited retinal degenerative disease that often results in nearly complete blindness, affects roughly 200,000 Europeans and has been designated by the World Health Organization as an orphan disease. In 2011, the Argus II, which is intended to help the RP patients with complete blindness, received a CE Mark, making it the first approved treatment for severe retinitis pigmentosa anywhere in the world. "We have seen a tremendous acceptance from the German and Italian government to bring Argus II to Retinitis Pigmentosa patients at no cost for patients, and we hope to see a similar level of support from England, France and other European countries", said Dr Gregoire Cosendai, head of Europe for Second Sight.
Provided by European Science Foundation
- USC researchers begin tests on next generation of retinal implant Feb 16, 2007 | not rated yet | 0
- Eye implants make vision-restoring progress Jul 18, 2012 | not rated yet | 0
- First in New York: Bionic technology aims to give sight to woman blinded beginning at age 13 Oct 21, 2009 | not rated yet | 0
- First blind patients in the UK has retina implant May 03, 2012 | not rated yet | 0
- Artificial retina helps some blind people Feb 14, 2011 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Absorption of light by spherical nanoparticle
49 minutes ago Hello Can anyone tell me how the absorption of a polystyrene nanoparticles scales as a function of its diameter. The particle is spherical and...
Solvability of a circuit
5 hours ago Let's say I have a circuit consisting only of a finite number of batteries and resistors, all ideal. Given an arbitrary shape of this circuit, will I...
Question about perception of colors around light sources
8 hours ago When I look at a distant light source (like car headlights, or street lamp lights) I notice colors of the visible spectrum (as separated (as in after...
Does a charged particle rotate when traveling through a static Bf?
10 hours ago I have been looking at mass spectrometers, in particular the interactions between the Bf ind of a charged particle in motion in a static Bf of the...
Find a link between physics and assignment problems
11 hours ago Hi ! I've been working about assignments problems and how to solve them. I will have to do a presentation about it in few weeks. However, I'll...
Light as a source of electricity
11 hours ago Hello Dear Fellows! We all know that light is an electromagnetic wave and also we know that an antenna receives EM waves and...
- More from Physics Forums - Classical Physics
More news stories
The most common cause of failure after glaucoma surgery is scarring at the surgical site, so researchers are actively looking for ways to minimize or prevent scar formation. Previous work had suggested that vascular endothelial ...
Ophthalmology May 17, 2013 | not rated yet | 0 |
New research is emphasizing the importance of regular screenings for glaucoma, a disease that deteriorates the optic nerve over time and is a leading cause of irreversible blindness worldwide. The onset of glaucoma is associated ...
Ophthalmology May 17, 2013 | not rated yet | 0 |
The University of Nottingham and Nottingham University Hospitals NHS Trust, have been working with Sony Computer Entertainment Europe (SCEE) to develop special 3-D glasses and games to help treat children ...
Ophthalmology May 08, 2013 | not rated yet | 0
The first successful cornea transplant with donor endothelial tissue preloaded by an eye bank has been performed at Massachusetts Eye and Ear in Boston, Mass. Roberto Pineda II, M.D., Director of the Refractive Surgery Service ...
Ophthalmology May 07, 2013 | 5 / 5 (1) | 0
Adding omega-3 fatty acids did not improve a combination of nutritional supplements commonly recommended for treating age-related macular degeneration (AMD), a major cause of vision loss among older Americans, ...
Ophthalmology May 06, 2013 | 3 / 5 (2) | 0 |
12 hours ago | 4.8 / 5 (4) | 0 |
12 hours ago | 5 / 5 (2) | 0 |
11 hours ago | not rated yet | 0 |
11 hours ago | 5 / 5 (2) | 0 |
15 hours ago | not rated yet | 0
Gourmands and foodies everywhere have long recognized ginger as a great way to add a little peppery zing to both sweet and savory dishes; now, a study from researchers at Columbia University shows purified components of the ...
11 hours ago | not rated yet | 0